FILTER

FILTERED INTERVIEW RESULTS

Himanshu Gadgil

CEO, ENZENE BIOSCIENCES

"From an innovation point of view, breaking the US$40/gram cost barrier for production of mAbs is a key objective this year."

Mining

United States

George Bee

PRESIDENT AND CEO, U.S. GOLD CORP

Western USA Mining 2025 - Digital Interactive

"Our permitted status positions us favorably to capitalize on these market conditions, with the lower cost CK project production being attractive, particularly as established gold producers struggle to maintain production levels."

United States

Pharma & Life Sciences

Mike Radomsky

PRESIDENT, CMC PHARMACEUTICALS

"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."

United States

Pharma & Life Sciences

Andrea Confetti and Roberto Fanelli

EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS

"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."

Mining

Canada

United States

Chris Dougherty

PRESIDENT AND CHAIRMAN, NORDMIN ENGINEERING

Ontario Mining and Toronto's Global Reach 2025

"Given the industry’s challenges, including cost increases and procurement delays, working as a team is essential."

Mining

United States

Charles Kocsis

PROFESSOR & FORMER DEPARTMENT CHAIR - DEPARTMENT OF MINING ENGINEERING, THE UNIVERSITY OF UTAH

"Our focus is on advancing innovations in mine automation, efficient ventilation, mine design, and cooling systems to boost productivity and prioritize worker safety."

United States

Pharma & Life Sciences

Donna LaVoie

FOUNDER AND CEO, LAVOIEHEALTHSCIENCE

"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."

United States

Pharma & Life Sciences

Debbie Hart

PRESIDENT AND CEO, BIONJ

"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."

United States

Pharma & Life Sciences

David Short

SR. MANAGER, BUSINESS DEVELOPMENT - US & CANADA, PROCOS S.P.A.

"Procos is poised for transformative growth in 2025. Our R11 facility will significantly enhance our small-scale production capacity, enabling us to meet the growing demand for high-quality, specialized APIs in the US market."